Mazindol in Obesity with Known Cardiac Disease A Clinical Evaluation

Abstract

A double-blind twelve-week investigation of mazindol, a new anorexic agent, was carried out in obese patients with stable cardiac disease. The drug was administered in a dosage of 1 mg three times daily, leading to a significant (p < 0·001) loss of body weight (9·8 lbs). The underlying cardiac disease was not adversely affected.